

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

VOLUNTARY ANNOUNCEMENT

**HEFEI SUBSIDIARY AWARDED “2025 INNOVATIVE TECHNOLOGY
RISING STAR ENTERPRISE” TITLE**

This announcement is made voluntarily by Biosino Bio-technology and Science Incorporation (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide the Company’s shareholders and investors with the latest information.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that at the 2026 New Year Gathering for Enterprises hosted by Hefei Economic & Technological Development Area on 4 February 2026, the Company’s indirect non-wholly owned subsidiary, Biosino Hefei Medical Technology Co., Ltd. (“**Biosino MT (Hefei)**”), was awarded the honorary title of “2025 Innovative Technology Rising Star Enterprise of Hefei Economic & Technological Development Area” in recognition of its innovation capabilities and robust development potential in the in vitro diagnostics field. This award, presented by the Party Working Committee and Management Committee of Hefei Economic & Technological Development Area, serves as an authoritative acknowledgement of Biosino MT (Hefei)’s past achievements in technological innovation, and further demonstrates its future development prospects.

Biosino MT (Hefei)’s independently developed 4-laser 21-color BioCyteX (Clinical) High-End Flow Cytometer has officially obtained certification (Anhui Medical Device Registration Certificate No. 20252220150), making it the first domestically produced brand to receive a registration certificate for a high-end 4-laser flow cytometer in China. The product’s performance reaches the top standard among domestic brands, being comparable to international imported brands, thus marking a substantial breakthrough for domestic flow cytometry in advanced fields and actively responding to the national call for “domestic substitution”. Featuring four sophisticated semiconductor lasers operating in synergy, the instrument can simultaneously excite 21 fluorescent dyes and acquire 24 key parameters. Its detection sensitivity, resolution, and stability all reach international leading levels, meeting critical clinical requirements in high-complexity immune phenotyping and minimal residual disease (MRD) monitoring. The successful approval of BioCyteX flow cytometer signifies a pivotal advancement, moving domestic products from “follower” to “peer” status in complex optical design and multi-color fluorescence analysis.

Since its establishment in Hefei Economic & Technological Development Area in 2022, Biosino MT (Hefei) has leveraged the area's high-quality innovation resources to accelerate its growth, achieving multiple breakthroughs in the R&D and market promotion of high-end flow cytometers and supporting reagents. Biosino MT (Hefei)'s products have obtained several national and international medical device certifications, with business operations covering 31 provinces, municipalities, and autonomous regions across China, and extending to overseas markets.

Receiving this honor not only enhances the Group's influence in R&D and technological innovation, but also lays a solid foundation for the Group's further expansion into the healthcare sector. The Company will continue to strongly support the technological innovation and industrial development of its subsidiaries, actively expand high-quality businesses, enhance competitiveness, and create greater value for shareholders.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Peng
Chairman, President and Executive Director

Beijing, China, 9 February 2026

As at the date of this announcement, the members of the Board comprises:

Chairman, President and Executive Director
Mr. Chen Peng

Vice Chairman and Executive Director
Mr. Li Zhonghua

Executive Director
Mr. Chen Zhengyong

Non-executive Director
Ms. Kang Rui

Independent non-executive Directors
Prof. Shen Jiangang, Mr. Fan Xiaoliang and Prof. Jin Tengchuan

*This announcement is made in compliance with the requirements of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) to disclose information concerning the Company. The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement in this announcement misleading.*

This announcement will remain on the “Latest Listed Company Announcements” page on the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the Company's website at www.zhongsheng.com.cn.